AstraZeneca Investor Conference Presentation Deck
Capital allocation priorities
Effective deployment of capital to ensure opportunities for further growth
S&P Global
A
A-2
Stable
Long term:
Short term:
Outlook:
Acquisitions
Strong investment grade rating
CINCOR
ALEXION
AstraZeneca Rare Disease
THERAPEUTICS
neo gene
THERAPEUTICS
TeneoTwo Inc
Value-adding business development
Collaborations
Daiichi-Sankyo
CAELUM
BIOSCIENCES
AMGEN
IONIS
GRAIL
MOODY'S
Long term:
Short term:
Outlook:
mind
MERCK
AG
sanofi ROBIO
C 4
X D
SCORPION
A3
P-2
Stable
"T'EMPUS
In-licensing
UNIVERSITY OF
OXFORD
VANDERBILT
UNIVERSITY
HARBOUR
BIOMED
neurimmune
Reinvestment in the business
R&D spend:
low twenties
percentage of
Total Revenue¹
Late-stage
development
Discovery
Medical Affairs
and other
Returning value
Early-stage
development
6
1. Core R&D Expense as a percentage of Total Revenue was 21.5% in 9M 2022. 2. Progressive dividend policy defined as dividend per share either stable or increasing in US dollar terms. R&D = Research & Development.
illustrative split of
R&D investment
Progressive dividend policy²
3View entire presentation